Further ex vivo testing demonstrated that downregulation of two novel regulators predicted, PKLR and CHCHD6, lowered mitochondrial respiration and led to a shift toward glycolytic metabolism in the liver mitochondria, thus highlighting mitochondria dysfunction as a key mechanistic driver of NAFLD in the liver [82]. Here, CHCHD6 is linked to metabolic dysfunction-associated steatotic liver disease.